what is diazepam (valium)? benzodiazepine drug, used to treat spasticity in ms patients quizlet
P T. 2014 Jun; 39(6): 427-435.
Considerations for the Appropriate Apply of Skeletal Muscle Relaxants for the Management Of Astute Low Back Pain
Corey Witenko, PharmD, BCPS, Robin Moorman-Li, PharmD, BCACP, Ballad Motycka, PharmD, BCACP, Kevin Duane, PharmD, Juan Hincapie-Castillo, PharmD, Paul Leonard, PharmD, and Christopher Valaer, PharmD
INTRODUCTION
For the by three decades, depression dorsum pain has consistently been ranked among the pinnacle five most common reasons for physician visits in the United States.1 – 3 Withal, there is little consensus on a proper diagnosis and optimal treatment strategy for these patients. The three main classifications of low dorsum pain include: nonspecific depression back hurting, dorsum pain associated with radiculopathy or spinal stenosis, and dorsum hurting correlated with another specific spinal cause (i.east., malignancy, infection, or vertebral fracture).1 Nonspecific low dorsum pain is primarily astute without an identifiable crusade and typically resolves in less than four weeks.iv However, a significant portion of patients may feel persistent back pain well across the acute episode, affecting health care costs and limiting daily activities.5
The American Pain Society and the American College of Physicians published guidelines in 2007 for low back pain, recommending acetaminophen or nonsteroidal anti-inflammatory drugs (NSAIDs) as start-line treatment for nearly patients. This recommendation is primarily due to the favorable side-effect contour of these agents compared with other options equally opposed to superior efficacy.1 Afterwards failure of a beginning-line agent, skeletal muscle relaxants, benzodiazepines, and opioids may be initiated based on evidence of temporary additional pain relief.i
In general, muscle relaxants are controversial alternatives that have efficacy in nonspecific back pain but deport risks of adverse effects and increased cost. Although they are not recommended equally primary treatment, 35% of patients are prescribed muscle relaxants for nonspecific depression back hurting, and 18.5% receive initial muscle relaxant therapy.2 , 6 , 7 Patients are often prescribed these agents for the handling of acute back hurting, and many experience relief within several weeks of starting therapy.8 For example, patients receiving cyclobenzaprine were more likely to report symptomatic improvement at two weeks compared with placebo (number needed to treat = 3).8 Given the frequency of apply, the questionable role in the treatment of back pain, and the potential for misuse, information technology is imperative for clinicians to be aware of the facts regarding ordinarily used muscle relaxants in the United States.
EVIDENCE FOR THE USE OF SKELETAL MUSCLE RELAXANTS
Recent literature analyzing the prevalence of muscle relaxant use is scarce. Some clinicians would hold that the medications in this form tend to be used more than frequently than necessary, only clear data are defective. IMS Health data from 2003–2004 showed carisoprodol, cyclobenzaprine, and metaxalone deemed for more 45% of all prescriptions written for the management of musculoskeletal pain.9 Dillon et al. sought to define U.S. usage patterns using data from the third National Health and Nutrition Test Survey (NHANES III).10 In this cross-sectional prevalence study, the authors concluded that approximately two million U.S. adults used skeletal muscle relaxants. Interestingly, the study found that although two-thirds of patients taking these agents had a recent history of back pain, the prevalence of these medications was only 4% amongst all participants who reported a history of back hurting in the previous year (95% CI, ii.9%–five.2%). In addition, the study showed that 44.5% of users took muscle relaxants for more than than a yr (95% CI, 35.7%–53.three%). This finding is of business organization because each amanuensis is recommended but for brusque-term use and has yet to be studied in chronic management. Sociodemographic analysis of the data shows users' median age was 42.3 years (95% CI, 38.ane–47.viii), and 16% were more than 60 years onetime.10 While the findings in this study offer some data on muscle relaxant apply, it is of import to call up that the NHANES III survey presents information from 1988 to 1994.
A systematic review indicated that skeletal muscle relaxants were effective in the short-term relief of acute low dorsum pain when compared with placebo.half-dozen However, these agents were associated with a 50% increased take a chance of adverse events (AEs) with a relative take chances of 1.50 (95% CI, ane.14–1.98).6 Specifically, fundamental nervous organization (CNS) adverse events had a stronger association with skeletal muscle relaxant use, with a relative risk of 2.04 (95% CI, one.23–three.37).half dozen In addition to sedation, patients may experience headaches, blurred vision, and dependency with the utilise of these agents.
There are very few loftier-quality studies comparison the efficacy of skeletal muscle relaxants.vi Merely 1 high-quality head-to-head report shows superiority of carisoprodol to diazepam.xi Additionally, no studies have been conducted to evaluate skeletal muscle relaxants compared with first-line treatments (eastward.g., acetaminophen or NSAIDs). Therefore, if a skeletal musculus relaxant is needed, an appropriate selection should exist based on individual factors including elapsing and severity of symptoms, prior response to medications, potential side furnishings, desired benefits, comorbid atmospheric condition, and price.5 , vi
One element of selecting the right treatment involves ensuring that the agent is used in appropriate populations. The Beers Criteria for Potentially Inappropriate Medication Utilise in Older Adults is a collection of recommendations from health care providers on medications with potential AE risks that outweigh most benefits for apply. Considering they cause CNS depression, several skeletal muscle relaxants are on the Beers list, including carisoprodol, chlorzoxazone, cyclobenzaprine, metaxalone, methocarbamol, and orphenadrine.12 These agents are poorly tolerated in patients more than 65 years old due to anticholinergic AEs, sedation, and run a risk for falls and fractures.12 Despite this risk, approximately 15% (300,000) of annual prescriptions for skeletal muscle relaxants are given to patients over the age of 65.10 In a nationwide case-control report in the Medicare Reward population, the use of skeletal muscle relaxants was associated with a twoscore% increment in fracture adventure (adapted odds ratio [OR] = one.xl; 95% CI, one.15–one.72, P < 0.001).thirteen Furthermore, the risk increased with the concomitant use of long-acting benzodiazepines (adapted OR = 2.66; 95% CI, 1.94–three.65).13 Although this study was retrospective, the results support the nomenclature of these agents on the Beers list.
Billups et al. conducted a pre-post cohort analysis to compare the incidence of concrete injury in patients before and afterward the initiation of a skeletal muscle relaxant. Although retrospective in pattern and with limitations, this study showed a pocket-size, statistically significant increase in injury including fractures, contusions, lacerations, and falls within the first 60 days of initiation of a skeletal muscle relaxant.14 These results do not imply that use should be avoided in all geriatric patients merely advise clinicians should be cautious, personalize therapy, and assure that the benefits outweigh the risks of side effects.
When because the overuse of these medications, information technology is of import to understand the consequences and possible dangers to the public. The Substance Abuse and Mental Wellness Services Administration and the U.S. Department of Wellness and Human being Services released national estimates of drug-related visits to hospital emergency departments (EDs) based on information from the Drug Abuse Warning Network (DAWN), a public health surveillance system of not-federal hospitals operating 24-hr EDs. Participating hospitals retrospectively review cases involving all types of drug use, including illegal, prescription, and over-the-counter medications. Estimates are fabricated each agenda year, assuasive for comparisons between years that bear witness changes in prevalence among the unlike classes of medications.
In the 2011 DAWN update, 33.nine% of the ED visits from anxiolytics, including benzodiazepines, were associated with nonmedical apply of prescription drugs.15 Fifty-fifty though the prevalence is lower than other agents such as analgesics, skeletal muscle relaxants are still a major concern in the U.S. In 2011, an estimated 53,000 ED visits were acquired by muscle relaxant misuse or abuse, and 18% of these cases involved concomitant booze consumption.15 Carisoprodol was the most common skeletal musculus relaxant misused, with 25,528 cases, followed by cyclobenzaprine with 11,551 cases, contributing two.1% and 0.9%, respectively, of all visits involving nonmedical apply of pharmaceuticals.15 When investigating rates of suicide attempts, musculus relaxants were the primary agent in 4.8% of cases.15 Cyclobenzaprine was the virtually common agent (two.5%), followed by carisoprodol (1.0%). Since 2004, at that place has been an 84% increase in skeletal muscle relaxant interest in suicide attempts, with cyclobenzaprine accounting for more than half of such visits.15
In an effort to investigate the potential shift in abuse or misuse of agents afterwards carisoprodol was reclassified equally a controlled substance, a search was conducted on skeletal muscle relaxant exposures reported to the Florida Poison Information Heart Network from 2009 to 2012. Data extracted included intentional abuse or misuse of carisoprodol, cyclobenzaprine, and a combination of other musculus relaxants. The frequency of carisoprodol exposure in 2012 subsequently its reclassification every bit a controlled substance was 75 cases, compared with an average of 132 cases annually between 2009 and 2011.16 Interestingly, the frequency of cyclobenzaprine exposure decreased to 27 cases in 2012 compared with an average of 36 cases annually betwixt 2009 and 2011.sixteen Data on other muscle relaxant exposures showed variation among years without a clear increase in abuse or misuse after carisoprodol became a controlled substance.16 Boosted analysis must be washed to assess the impact of the reclassification of carisoprodol on the frequency of misuse and abuse of other, noncontrolled skeletal muscle relaxants.
Course OVERVIEW
Skeletal musculus relaxants include a variety of structurally unrelated compounds that can be classified into 2 main categories: antispasticity and antispasmodic medications. These agents have different indications, mechanisms of action, and side-effect profiles. Understanding these differences can improve selection of an appropriate agent to optimize patient-specific therapy.
Antispasticity agents work on the spinal string or directly on the skeletal muscles to improve muscle hypertonicity and involuntary spasms. Spasticity is divers as the increased muscle tone or stiffness that leads to undesirable and uncontrolled movements.1 These medications are used for spastic conditions such every bit cerebral palsy, multiple sclerosis, and spinal cord injuries. A common antispasticity agent used in do is baclofen. Dantrolene is also an antispasticity agent, simply it should not be used for low dorsum pain because its efficacy has not been proven for musculoskeletal conditions. In addition, dantrolene has a boxed alarm associated with the potential for fatal hepatotoxicity.17
Antispasmodics decrease muscle spasms through alterations of CNS conduction. They are divided into benzodiazepines, which inhibit transmission on the postsynaptic γ-aminobutyric acid (GABA) neurons, and nonbenzodiazepine agents, which act at the brain stem and spinal cord.1 Benzodiazepines (east.one thousand., diazepam) are used as sedatives, anxiolytics, and anticonvulsants, and have been shown to have efficacy in the astute management of low back pain.vi Other antispasmodics unremarkably prescribed for the reduction of muscle spasms include: carisoprodol, cyclobenzaprine, metaxalone, and methocarbamol.
In general, antispasticity agents and antispasmodics are non interchangeable and should not be substituted for 1 another. All the same, some muscle relaxants, such as tizanadine and diazepam, conduct indications approved by the Food and Drug Administration (FDA) for both conditions (Effigy ane). Limited evidence exists for comparing one agent with another, and then selecting an optimal agent relies on important patient-specific factors such as risks for side effects, potential drug interactions with concomitant therapies, and total cost.6
Classification of Skeletal Muscle Relaxants
Indications, dosages, precautions, and other characteristics of skeletal musculus relaxants are summarized in Table i.
Table 1
Skeletal Muscle Relaxants
| Medication | Indication | Common Dosage | Metabolism | Dose Adjustments |
|---|---|---|---|---|
| Antispasticity Agents | ||||
| Baclofen (Lioresal) | Spasticity | v mg three times daily Max: 80 mg daily | Hepatic (15%) | None |
| Dantrolene (Dantrium) | Spasticity, malignant hyperthermia | Initial: 25 mg daily Maintenance: 25–100 mg upwardly to 4 times daily | Hepatic (all-encompassing) | None |
| Antispasmodic Agents | ||||
| Carisoprodol (Soma) | Astute musculoskeletal pain | 250–350 mg iii times a day and at bedtime Max: 1,400 mg daily | Hepatic (2C19) Active metabolite: meprobamate | Liver disease: Use lower initial dose and increase gradually equally needed/tolerated |
| Chlorzoxazone (Parafon Forte DSC) | Astute musculoskeletal hurting | 500 mg 3–4 times daily Max: 750 mg three–iv times daily | Hepatic (glucuronidation) | None |
| Cyclobenzaprine (Amrix) | Acute musculoskeletal hurting | IR: 5 mg 3 times daily Max: 10 mg 3 times daily ER: 15 mg daily Max: 30 mg daily | Hepatic (CYP3A4, 1A2) | Renal, none; hepatic, use with caution |
| Metaxalone (Skelaxin) | Acute musculoskeletal pain | 800 mg three–iv times daily | Hepatic (CYP1A2, 2D6, 2E1, 3A4) | Contraindicated in astringent hepatic and renal dysfunction |
| Methocarbamol (Robaxin) | Acute musculoskeletal pain | Initial: i,500 mg 4 times daily for 2–3 days Maintenance: 750 mg every 4 hours, ane,500 mg by mouth 3 times daily, or one,000 mg four times daily Max: 4 g daily | Conjugation, dealkylation, and hydroxylation | None |
| Orphenadrine (Norflex) | Acute musculoskeletal pain | 100 mg 2 times daily | Hepatic (extensive) | None |
| Antispasticity and Antispasmodic Agents | ||||
| Diazepam (Valium) | Relief of skeletal muscle spasm | 2–ten mg 3 to iv times daily | Hepatic (2C19, 3A4) | Renal, none; hepatic, decrease by l% |
| Tizanidine (Zanaflex) | Spasticity | Initial: 4 mg up to iii times daily; may titrate to optimal effect in 2–iv mg increments as needed to a max of 3 doses in 24 hours | Hepatic (1A2) | Renal, apply with caution if CrCl < 25 mL/min; hepatic, avoid utilise in astringent impairment |
| Medication | Beers Criteria | Special Precautions | Agin Effects | Clinical Pearls |
| Antispasticity Agents | ||||
| Baclofen (Lioresal) | No | Geriatric: five mg 2–3 times daily; use lowest constructive dose | CNS low | Boxed warning: Avoid precipitous discontinuation due to risk of withdrawal |
| Dantrolene (Dantrium) | No | May crusade lord's day sensitivity | Major hepatic impairment including fatal hepatitis, CNS depression, difficulty swallowing | Boxed alarm: risk for hepatotoxicity with chronic use; routine employ not recommended |
| Antispasmodic Agents | ||||
| Carisoprodol (Soma) | Yes | Has been subject to abuse, dependence, withdrawal, misuse, and criminal diversion | Drowsiness, dizziness, headaches, somnolence, seizure | Schedule 4 Agile metabolite with barbiturate effects; some bear witness suggests sedation is main mechanism of action without direct effects on skeletal muscle. Limit use to 2–3 weeks. |
| Chlorzoxazone (Parafon Forte DSC) | Yes | Idiosyncratic and unpredictable hepatotoxicity (rare but serious) | CNS depression | Periodic LFTs recommended during chronic utilise |
| Cyclobenzaprine (Amrix) | Yes | Caution with elderly and hepatic impairment | Anticholinergic effects, CNS depression, rare arrhythmias | Construction similar to tricylic antidepressants. Do not use longer than two–three weeks; do not use inside fourteen days of monoamine oxidase inhibitors. |
| Metaxalone (Skelaxin) | Yes | Monitor liver function in mild-to-moderate hepatic dysfunction | CNS depression, nausea, vomiting; rare: jaundice, hemolytic anemia, elevated LFTs | Mechanism associated with sedative backdrop; take with nutrient |
| Methocarbamol (Robaxin) | Aye | Geriatrics, liver, and renal impairment: Use lower initial doses and increase gradually equally needed/tolerated | Dizziness, headache, lightheadedness | Mechanism associated with CNS low; drug may change colour of urine to brown, blackness, or green |
| Orphenadrine (Norflex) | Yes | Circumspection in patients with heart failure (palpitations, tachycardia); do not shell | Anticholinergic effects | Euphorigenic and analgesic backdrop; must taper in chronic utilise |
| Antispasticity and Antispasmodic Agents | ||||
| Diazepam (Valium) | Yes | Elderly: two–2.5 mg one–ii times daily; titrate gradually equally tolerated | Drowsiness, fatigue, and ataxia | Schedule 4 Avoid sharp discontinuation subsequently extended therapy |
| Tizanidine (Zanaflex) | No | Elderly: employ with circumspection due to decreased clearance | Somnolence, xerostomia, and weakness | Concomitant use with other psychotropics may crusade additive sedation; monitor liver function; avoid rapid discontinuation |
Antispasticity Agents
Baclofen
Baclofen is a centrally acting skeletal muscle relaxant that is structurally like to γ-aminobutyric acid (GABA), differing only in the presence of an boosted phenylchloride group. Baclofen acts on the presynaptic GABAA site, decreasing synaptic manual on the spinal cord. It has FDA-labeled indications for musculus spasms and spasticity related to CNS lesions, mainly multiple sclerosis and spinal cord lesions.18 Although information technology is equivalent to other antispasticity agents, it has a decreased occurrence of CNS depression.
Dosing regimens vary by indication, but generally are initiated at 5 mg three times daily, and can exist titrated by v mg per dose every three days. The effective range is xl mg to 80 mg in divided doses given three or four times daily. Elevation blood concentrations following administration occur in three to 4 hours.18 Well-nigh fifteen% of the drug is metabolized in the liver by deamination, and the drug is primarily excreted (70% to 85%) past the kidneys.18
At that place are no recommended dosing adjustments for hepatic or renal dysfunction; however, due to the extensive renal elimination, contempo literature suggests a dose reduction should be considered in patients with renal impairment.nineteen In a pharmacokinetic assay comparing 21 patients with normal and dumb renal function, oral baclofen 5 mg clearance was reduced by about 34%, 49%, and 64% in patients with mild, moderate, and severe chronic kidney disease, respectively.19 Equally the estimated glomerular filtration charge per unit (eGFR) decreased, baclofen elimination decreased. This allowed for increased serum concentrations and potentially increased AE risks. Based on these results, 33%, 50%, and 66% dose reductions should be considered in patients with mild (creatinine clearance [CrCl] of 50 mL/min or more than), moderate (CrCl of 30 mL/min or more), and astringent (CrCl of less than xxx mL/min) renal dysfunction, respectively.nineteen The drug is effectively removed by hemodialysis in the case of excessive accumulation or overdose.
Oral baclofen carries a boxed warning regarding abrupt discontinuation, which may cause defoliation, hallucinations, seizures, and exacerbations of spastic conditions due to precipitation of withdrawal.18 A gradual reduction in dose over several weeks is recommended when discontinuing baclofen.18 Mutual AEs include weakness, dizziness, drowsiness, vertigo, and insomnia.18
Dantrolene
Dantrolene is a skeletal muscle relaxant structurally related to phenytoin. Information technology has a unique peripheral mechanism of activeness, differing from the centrally acting agents. Dantrolene interferes with the release of calcium ions from the sarcoplasmic reticulum in the skeletal muscle prison cell. This disruption slows the contraction cycles of muscle cells occurring in cancerous hyperthermia, making dantrolene an ideal agent for the treatment of this condition.xx This agent is FDA-approved for the treatment of spasticity of upper neuronal disorders, including spinal string injury, multiple sclerosis, and cerebral palsy.twenty
Oral dantrolene carries a boxed alert regarding the hazard of hepatotoxicity with chronic use17 , xx and should not be used in the treatment of depression back pain.17
Antispasmodic Agents
Metaxalone
Metaxalone is a CNS depressant used for acute musculoskeletal spasmodic hurting. Although commonly classified as a muscle relaxant, metaxalone does non act direct on skeletal muscle. While its mechanism is not fully understood, its antispasmodic effects are attributed to its allaying properties. Metaxalone is indicated only as adjunct treatment to physical therapy for acute musculoskeletal pain.21 The recommended dosing regimen is 800 mg given three to 4 times daily.21 The onset of activity can be seen within an hour, and patients will feel furnishings for upward to 6 hours. Meals higher in fat announced to increase bioavailability, so metaxalone should be taken with nutrient.
Metaxalone undergoes hepatic metabolism through the cytochrome P450 (CYP) isoenzymes 1A2, 2D6, 2E1, and 3A4, and metabolites are excreted in the urine.21 Other medications used concomitantly must be taken into consideration due to the hepatic metabolism past numerous CYP enzymes. Common reported AEs include dizziness, drowsiness, nausea, and vomiting. Rare simply serious AEs include hemolytic anemia, leukopenia, and jaundice. Metaxalone is contraindicated in severe hepatic and renal dysfunction; liver role tests should be monitored with therapy from baseline in mild-to-moderate liver dysfunction.21
Methocarbamol
Methocarbamol is an oral and parenteral centrally acting muscle relaxant indicated as an adjunct to physical therapy for the relief of acute musculoskeletal pain. Similar to many medications in this class, the exact mechanism of action is unknown, merely its effects may be due to general CNS depression. Information technology is available in 500-mg and 750-mg tablets; the initial recommended dose is one,500 mg four times daily for two to three days for the treatment of acute musculoskeletal pain.22 Maintenance therapy is recommended at a decreased dose of 4 g to 4.5 g divided into three to six doses daily.
After oral assistants, methocarbamol is speedily and completely captivated. It is extensively metabolized past dealkylation and hydroxylation, and conjugation may be involved as well. Virtually all metabolites and remaining unchanged methocarbamol are excreted in the urine. The most mutual AEs are lightheadedness, dizziness, and drowsiness. In that location are insufficient data on its efficacy; however, information technology can be helpful in patients who cannot tolerate the stronger sedative effects of other muscle relaxants.22
Orphenadrine
Orphenadrine citrate is an analog of diphenhydramine that is used for the treatment of musculus spasm associated with acute painful musculoskeletal conditions. It indirectly alleviates muscle pain through fundamental atropine-like effects, and has some euphorigenic and analgesic properties. It comes in 100-mg extended-release tablets that cannot exist crushed. It is recommended for brusk-term employ, and must be tapered slowly if apply becomes chronic.23
Orphenadrine undergoes all-encompassing hepatic metabolism through the CYP450 enzyme system, but it is a minor substrate and weak inhibitor, which limits business concern about drug interactions. Peak effects are typically seen inside two to iv hours and tin can concluding upwards to half dozen hours. Since patients may experience cardiovascular side effects such as palpitations and tachycardia, caution must exist taken for patients with heart failure, tachycardia, or cardiac arrhythmias. Due to anticholinergic side effects, utilize in the elderly is generally not recommended. Common AEs include constipation, urinary retention, and confusion.23
Chlorzoxazone
Chlorzoxazone is indicated for the symptomatic treatment of muscle spasms and hurting associated with acute musculoskeletal weather condition. It acts on the spinal cord and subcortical areas of the brain to inhibit polysynaptic reflex arcs involved in causing and maintaining skeletal muscle spasms. It comes in 375-mg, 500-mg, and 750-mg scored tablets; the recommended dosage is 500 mg three to four times daily, just a clinician may increment the dosage up to 750 mg iii to iv times daily if needed.24 Peak furnishings can be seen inside an hour and last up to half-dozen hours.
Similar to other agents in this course, chlorzoxazone tin can cause CNS side furnishings, such as dizziness, drowsiness, and light-headedness, and use in the elderly population is by and large not recommended. A rare only serious reported AE isidio syncratic and unpredictable hepatocellular toxicity. If symptoms such as fever, rash, dark urine, or jaundice develop, discontinue the medication immediately. Periodic liver function tests are recommended, specially during chronic use.24
Carisoprodol
Carisoprodol is an oral, centrally acting skeletal muscle relaxant indicated for the acute handling of musculoskeletal pain. The verbal mechanism of activeness remains unknown, but it is associated with altered neuronal communication at the reticular formation and spinal cord, causing CNS depression and a reduction in pain perception.25 Some evidence suggests that sedation is the main machinery of activity without directly affecting the skeletal muscle.26 It is bachelor in 250-mg and 350-mg tablets; administration is recommended three times daily and at bedtime.25 It has only been proven efficacious in the treatment of acute low back hurting, which limits its duration to two or three weeks. The onset of activeness is approximately 30 minutes and its effects can terminal for four to half dozen hours.25
Caution must be taken in patients with renal or hepatic dysfunction, equally in that location is bereft evidence of proper dosing in these populations. The most common AEs of CNS depression include dizziness, drowsiness, and headache, which tin be increased with extended employ and overuse. Carisoprodol is on the Beers list because the risks of side effects outweigh the potential benefits of treatment.12
Carisoprodol is extensively metabolized past CYP2C19, particularly to meprobamate, which has both allaying and anxiolytic properties.25 Since conversion to the active metabolite is done predominantly by CYP2C19, there are concerns regarding genetic polymorphisms affecting serum drug concentrations. Reports have shown a fourfold increase in carisoprodol exposure and a 50% reduced meprobamate exposure in individuals with polymorphisms compared to normal metabolizers.25 Hoiseth et al. sought to investigate the role of genetics in mortality related to carisoprodol toxicity. In this study, the variant alleles for the enzymes were not associated with an increased risk for mortality.27
At that place are limited data comparing carisoprodol to other skeletal musculus relaxants. Boyles et al. conducted a randomized, double-bullheaded trial of carisoprodol versus diazepam and found carisoprodol led to increased overall improvement in hurting scores with respect to muscle stiffness, activity, and relief.11 Rollings et al. conducted a high-quality written report with carisoprodol and cyclobenzaprine and plant no statistically significant differences in overall pain scores.28
The abuse potential of carisoprodol is derived from its adequacy to modulate GABAA function, and the active metabolite, meprobamate, can exacerbate this effect.29 Meprobamate is a Schedule IV controlled substance, introduced as an anxiolytic agent during the 1950s, with a mechanism of action similar to barbiturates. The one-half-life of meprobamate is approximately 10 hours merely can escalate to 48 hours in chronic use.xxx When it is used long-term, many patients may experience enhanced CNS depression due to the aggregating of the metabolites. Elderly patients and those with renal insufficiency are at a higher chance for this event. Chronic users of carisoprodol have an increased likelihood of experiencing withdrawal symptoms following sharp discontinuation. Symptoms of withdrawal include anxiety, indisposition, irritability, tremors, musculus twitching, and ataxia, which may be exacerbated with the metabolite accumulation.29 , 31
Co-ordinate to the Drug Enforcement Agency (DEA), drug-induced seizures from carisoprodol increased from three,988 in 2008 to more than than five,000 in 2010: more than lorazepam and methylphenidate, which have a common association with abuse. Diversion has become more than prevalent among legitimate medical practices and customs pharmacies, with tactics ranging from "medico shopping" to forged prescriptions. Reports of carisoprodol abuse grew more than frequent equally information technology came to exist seen as an easily accessible sedative that tin can augment or change the effects of other drugs. Carisoprodol employ has been reported among patients to increase the sedating furnishings of benzodiazepines or alcohol, prevent jitteriness during cocaine consumption, and help calm individuals afterwards cocaine use.30 Carisoprodol tin can also exist taken with other drugs to produce synergistic effects of extreme relaxation and euphoria.thirty
In 1996, the DEA suggested reclassifying carisoprodol as a controlled substance in response to increasing instance reports of effects similar to its meprobamate metabolite, which has been classified as a controlled substance in the U.Southward. since 1970. The FDA'south Drug Advisory Commission concluded that in that location was bereft evidence to support the change at that time.32 Betwixt 1994 and 2004, DAWN data showed that carisoprodol-related ED visits more than doubled, with an estimated 14,736 visits in 2004. In 2009, the frequency of ED visits doubled once more, with 29,980 cases of nonmedical carisoprodol utilize.xv The 2009 Monitoring the Futurity national survey reported that carisoprodol abuse was seen in 1.4% of high school seniors, a frequency higher than lorazepam and clonazepam.thirty
A survey of 40 individuals who had been taking carisoprodol for at least three months showed that half had a history of substance abuse. Of these xx individuals, 40% admitted taking more than prescribed, 30% admitted taking it for effects other than prescribed, 10% admitted taking it to augment furnishings of other drugs, and v% admitted taking it to counteract other drug effects.33 The same survey assessed 100 physicians' knowledge of carisoprodol and found that 95% knew meprobamate was a controlled substance but just 18% were aware that meprobamate was the active metabolite of carisoprodol.33
Due to the accumulating bear witness, on Jan eleven, 2012, carisoprodol became a Schedule Four medication under the Controlled Substances Deed of 1970.
Cyclobenzaprine
Cyclobenzaprine is structurally like to tricyclic antidepressants such as amitriptyline and nortriptyline. Its mechanism of action as a muscle relaxant is non fully understood, but it is idea to act on the supraspinal area of the brain stalk as an αtwo agonist at descending noradrenergic neurons.34 Evidence shows that cyclobenzaprine likewise has some serotonergic antagonism at the 5-HT2 receptor, which may contribute to its antispasmodic properties.35 Information technology is FDA-canonical for the relief of spasms associated with astute musculoskeletal weather unrelated to CNS disease. Patients can feel consolation of acute musculoskeletal pain and increased mobility.34 It is ofttimes used off-label for fibromyalgia, just has non been proven efficacious for treatment longer than 1 month.36
Cyclobenzaprine is available equally 5-mg and 10-mg immediate-release tablets and 15-mg and xxx-mg extended-release tablets.34 , 37 The current recommended dosing regimen starts at 5 mg three times daily (x mg at bedtime for fibromyalgia), and tin can be titrated to a maximum dose of ten mg iii times daily.34 The initial dose of the extended-release formulation, Amrix (Cephalon), is xv mg one time daily but may exist titrated to a maximum of 30 mg daily.37 Both formulations are recommended for use for upwardly to three weeks due to a lack of show for benefits of chronic use.38 In comparisons of safety and efficacy of firsthand-release versus extended-release formulations, patients experienced similar relief from local pain and brake of motion.39 , 40 The only deviation was a lower incidence of somnolence in the extended-release formulation.39 , xl
The almost common side effects patients may experience include dizziness and drowsiness. Due to the activity at cholinergic receptors, cyclobenzaprine can cause anticholinergic effects such equally dry oral cavity, blurred vision, constipation, and urinary memory. Like to tricyclic antidepressants, cardiac arrhythmias including QTc prolongation are possible, and apply may not be preferred in patients who have a history of arrhythmias or who are meantime taking medications that besides may prolong QTc.34 , 37
Cyclobenzaprine is metabolized primarily by CYP3A4 and CYP1A2. The half-life ranges from eight to 36 hours and is heavily patient-specific. Caution should exist taken with use in the elderly due to a relatively long one-half-life and elevated drug concentrations that tin can greatly increase the adventure of drug-related AEs.41 This increased adventure in the elderly is generally due to decreased hepatic metabolism that can pb to average steady-land plasma concentrations more than 1.seven times greater than the concentrations in younger adults.34 , 41
Antispasmodic and Antispasticity Agents
Tizanidine
Tizanidine is a centrally acting αtwo-adrenergic agonist canonical for the management of spasticity. It is idea that the drug exerts its effects through an increase in the presynaptic inhibition of motor neurons with no direct issue on skeletal muscle fibers.42 Tizanidine is available as 2-mg and four-mg tablets and every bit 2-mg, 4-mg, and 6-mg capsules. It is of import to note that the capsules and tablets are bioequivalent under fasting conditions, but not when taken with meals. The quantity absorbed from the capsule under fed atmospheric condition is approximately lxxx% compared to the tablet formulation. The initial dosing recommendation is 4 mg given upwardly to three times daily at half-dozen- to eight-hour intervals.42 The manufacturer gives this recommendation, despite the lack of efficacy in studies with doses less than eight mg, due to concerns with dose-dependent AEs. The dose tin can exist increased in 2-mg to 4-mg increments to accomplish optimal consequence, and the full daily dose should non exceed 36 mg.42
The virtually mutual side effects include dry oral cavity, somnolence, asthenia, and dizziness. Asymptomatic hepatic amino-transaminase elevations have been noted in patients taking tizanidine, so monitoring of liver enzymes is warranted every bit accounted necessary by the clinician. Precipitous discontinuation may induce a hyperadrenergic syndrome that tin can include reflex tachycardia and hypertension, tremor, feet, and hypertonicity.42 A recent case report showed that abrupt discontinuation of tizanidine given concomitantly with baclofen led to the development of delirium, extrapyramidal symptoms, and autonomic dysfunction in a patient with impaired renal role.43 This case highlights the risks of using more than one muscle relaxant that tin can lead to increased CNS depression.
Due to hepatic metabolism through the CYP1A2 pathway, concentrations of tizanidine are increased with concomitant administration of inhibitors of this cytochrome P450 such equally ciprofloxacin, fluvoxamine, cimetidine, famotidine, anti-arrhythmics, and oral contraceptives. Interaction with anti-arrhythmics warrants special attention: A recent written report showed that prolonged use of tizanidine can induce QT prolongation, especially in patients predisposed to arrhythmias and patients with impaired drug elimination.44 The manufacturer recommends that treatment with tizanidine should exist reserved for those activities and times when relief of spasticity is virtually important.42
Diazepam
Diazepam is a benzodiazepine used for its muscle relaxant activity in addition to its anxiolytic, antiepileptic, and hypnotic furnishings.45 It is believed that the drug plays a role in the increment in GABA-mediated presynaptic inhibition at spinal and supraspinal sites. This suggests that diazepam might be of value for spinal spasticity merely not for cognitive spasticity.
Diazepam is a controlled substance that is bachelor in ii-mg, 5-mg, and 10-mg tablets as well as solution for injection and oral administration. Per the manufacturer'due south recommendation, the oral dose for relief of skeletal musculus spasm is 2 mg to 10 mg three to four times daily.45 Starting the drug at a low dose and slowly titrating to a maximum daily dose of 30 mg is recommended due to concerns almost side effects. The most common AEs include drowsiness, fatigue, and ataxia.
Adequately few articles take been published in recent years looking at diazepam's effects in the treatment of spasms.45 A systematic review conducted by van Tulder et al. highlighted studies that showed diazepam to exist inferior to carisoprodol in improving functional status in patients with depression back pain and to exhibit no improvement over tizanidine after seven days of assistants.6
When because the apply of diazepam, it is of import to note that older adults have increased sensitivity to benzodiazepines and slower metabolism of long-acting agents. Per the Beers Criteria, benzodiazepines should generally exist avoided in the elderly because of an increased hazard of cognitive impairment, delirium, falls, and fractures.12 Their apply may be appropriate for seizure disorders, benzodiazepine withdrawal, alcohol withdrawal, severe general anxiety disorder, and end-of-life care.12 Routine use for the treatment of low back hurting should be minimal based on this criteria and increased risks.
Decision
Skeletal muscle relaxants are effective agents used for the direction of acute nonspecific low back pain. Nonetheless, the risk of adverse drug events raises concern for their safety in routine apply. In the past decade, the overuse of some agents has grown drastically, with an increased incidence of adverse effects. In addition to sedation, patients may experience headache, dizziness, blurred vision, nausea, and vomiting.
The potential for corruption and dependency seen with carisoprodol resulted in its reclassification equally a controlled substance in 2012 by the DEA. Ideally, this agent should be used with caution due to lack of efficacy, abuse potential, and risk for active metabolite accumulation.
The medications in this class are unremarkably used to treat acute musculoskeletal back pain, only they are often taken in higher quantities and for longer durations than recommended. Since testify supports their use only for astute low dorsum hurting, they should be used temporarily for pain relief. This also prevents the extended masking of any underlying status causing the dorsum hurting.
There are no set guidelines as to which agents are preferred; therefore, clinical judgment with proper understanding of the drug characteristics and patient-specific parameters should guide appropriate drug option.vi Wellness care providers must use their judgment to weigh the pros and cons of prescribing a muscle relaxant while tailoring therapy to the individual needs of each patient. As evidence improves, recommendations can exist modified, allowing patients to achieve safe and constructive relief of their acute low dorsum pain.
Acknowledgments
The authors would similar to acknowledge the assistance of Dawn R. Sollee, PharmD, DABAT.
REFERENCES
1. Chou R, Qaseem A, Snowfall V, et al. Diagnosis and treatment of low dorsum pain: A articulation clinical practise guideline from the American College of Physicians and the American Hurting Society. Ann Intern Med. 2007;147(7):478–491. [PubMed] [Google Scholar]
2. See Due south, Ginzburg R. Skeletal muscle relaxants. Pharmacotherapy. 2008;28(2):207–213. [PubMed] [Google Scholar]
3. Run across S, Ginzburg R. Choosing a skeletal muscle relaxant. Am Fam Physician. 2008;78(3):365–370. [PubMed] [Google Scholar]
four. Carragee EJ. Persistent low back pain. N Eng J Med. 2005;352(18):1891–1898. [PubMed] [Google Scholar]
5. Atlas SJ, Deyo RA. Evaluating and managing acute low back pain in the acute care setting. J Gen Intern Med. 2001;xvi(2):120–131. [PMC free article] [PubMed] [Google Scholar]
half dozen. Van Tulder MW, Touray T, Furlan A, et al. Musculus relaxants for nonspecific low back pain: A systematic review within the framework of the Cochrane Collaboration. Spine. 2003;28(17):1978–1992. [PubMed] [Google Scholar]
7. Luo X, Pietrobon R, Curtis LH, Hey LA. Prescription of non-steroidal anti-inflammatory drugs and muscle relaxants for back pain in the United States. Spine. 2004;29(23):E531–537. [PubMed] [Google Scholar]
8. Browning R, Jackson JL, O'Malley PG. Cyclobenzaprine and back pain: a meta-assay. Curvation Intern Med. 2001;161(13):1613–1620. [PubMed] [Google Scholar]
ix. Toth PP, Urtis J. Ordinarily used muscle relaxant therapies for astute low back pain: a review of carisoprodol, cyclobenzaprine hydrochloride, and metaxolone. Clin Ther. 2004;26(9):1355–1367. [PubMed] [Google Scholar]
10. Dillon C, Paulose-Ram R, Hirsch R, et al. Skeletal muscle relaxant use in the United states: Data from the tertiary National Health and Nutrition Test Survey (NHANES III) Spine. 2004;29(eight):892–896. [PubMed] [Google Scholar]
eleven. Boyles W, Glassman J, Soyka J. Management of acute musculoskeletal weather: thoracolumbar strain or sprain. A double-bullheaded evaluation comparison the efficacy and rubber of carisoprodol with diazepam. Today'due south Ther Trends. 1983;1:1–16. [Google Scholar]
12. The American Elderliness Society 2012 Beers Criteria Expert Panel. American Geriatrics Social club updated Beers Criteria for potentially inappropriate medication utilise in the elderly. J Am Geriatr Soc. 2012;60(4):616–631. [PMC gratuitous article] [PubMed] [Google Scholar]
xiii. Person EP, Marcum ZA, Boyce R, et al. Year in review: Medication mishaps in the elderly. Am J Geriatr Pharmacother. 2011;ix(one):ane–ten. [PMC gratis article] [PubMed] [Google Scholar]
14. Billups SJ, Delate T, Hoover B. Injury in an elderly population before and later on initiating a skeletal muscle relaxant. Ann Pharmacother. 2011;45(4):485–491. [PubMed] [Google Scholar]
15. Substance Abuse and Mental Health Services Administration. Drug Abuse Warning Network, 2011: National Estimates of Drug-Related Emergency Department Visits. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2013. HHS Publication No. (SMA) 13-4760, DAWN Series D-39. [Google Scholar]
16. Florida Poison Information Center Network Query Builder. Jacksonville, Florida: Florida Poisonous substance Information Center Network database search engine; Available at: https://fpicn.info. Accessed July 30, 2013. [Google Scholar]
17. Chou R. Pharmacological management of low back pain. Drugs. 2010;70(4):387–402. [PubMed] [Google Scholar]
eighteen. Baclofen Tablet packet insert. Sellersville, Pennsylvania: Teva Pharmaceuticals USA; 2010. Jun, [Google Scholar]
19. Vlavonou R, Perreault 1000, et al. Pharmacokinetic label of baclofen in patients with chronic kidney illness: Dose adjustment recommendations. J of Clinical Pharmacology. 2014 Jan. doi: 10.1002/jcph.247. [epub alee of print] [PubMed] [CrossRef] [Google Scholar]
20. Dantrolene package insert. Rochester, Minnesota: JHP Pharmaceuticals, LLC; Nov, 2008. [Google Scholar]
21. Metaxalone package insert. Bristol, Tennessee: King Pharmaceuticals, Inc.; Apr, 2008. [Google Scholar]
22. Methocarbamol package insert. Philadelphia, Pennsylvania: Lennett Co., Inc.; Jan, 2007. [Google Scholar]
23. Ophenadrine citrate package insert. Schaumburg, Illinois: Sagent Pharmaceuticals; Dec, 2009. [Google Scholar]
24. Chlorzoxazone packet insert. Sayreville, New Jersey: Vertical Pharmaceutical.; Oct, 2010. [Google Scholar]
25. Soma (carisoprodol) package insert Charlotte. North Carolina: Vintage Pharmaceuticals, Inc; Jun, 2006. [Google Scholar]
26. Gonzalez LA, Gatch MB, Taylor CM, et al. Carisoprodol-mediated modulation of GABAA receptors: in vitro and in vivo studies. J Pharmacol Exp Ther. 2009;329(2):827–837. [PMC complimentary commodity] [PubMed] [Google Scholar]
27. Hoiseth G, Majid U, Morland J, et al. CYP2C19 genetics in fatal carisoprodol intoxications. Eur J Clin Pharmacol. 2012;68(11):1561–1565. [PubMed] [Google Scholar]
28. Rollings H. Management of astute musculoskeletal weather– thoracolumbar strain or sprain: a double-bullheaded evaluation comparison the efficacy of carisoprodol with cyclobenzaprine hydrochloride. Curr Ther Res. 1983;34:917–928. [Google Scholar]
29. Reeves RR, Burke RS. Carisoprodol: abuse potential and withdrawal syndrome. Electric current Drug Abuse Reviews. 2010;3(1):33–38. [PubMed] [Google Scholar]
30. Reeves RR, Burke RS, Kose South. Carisoprodol: update on abuse potential and legal status. Southern Medical Journal. 2012;105(xi):619–623. [PubMed] [Google Scholar]
31. Gatch MB, Nguyen JD, Carbonaro T, et al. Carisoprodol tolerance and precipitated withdrawal. Drug and Booze Dependence. 2012;123(1–3):29–34. [PMC free article] [PubMed] [Google Scholar]
32. Fass JA. Carisoprodol legal condition and patterns of abuse. Ann Pharmacother. 2010;44(12):1962–1967. [PubMed] [Google Scholar]
33. Reeves RR, Carter Bone, Pinkofsky HB, et al. Carisoprodol (Soma): abuse potential and physician unawareness. J Addict Dis. 1999;18(2):51–56. [PubMed] [Google Scholar]
34. Flexeril (cyclobenzaprine) package insert. Fort Washington, Pennsylvania: McNeil Consumer Healthcare; January, 2010. [Google Scholar]
35. Kobayashi H, Hasegawa Y, Ono H. Cyclobenzaprine, a centrally acting muscle relaxant, acts on descending serotonergic systems. Eur J Pharmacol. 1996;311(1):29–35. [PubMed] [Google Scholar]
36. Carette Southward, Bell MJ, Reynolds WJ, et al. Comparisons of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia. A randomized, double-blind clinical trial. Arthritis Rheum. 1994;37(1):32–twoscore. [PubMed] [Google Scholar]
37. Amrix (cyclobenzaprine hydrochloride) capsule, extended release package insert. Frazer, Pennsylvania: Cephalon, Inc.; December, 2008. [Google Scholar]
38. Chou R, Peterson M, Helfand One thousand. Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal atmospheric condition: a systematic review. J Pain Symptom Manage. 2004;28(two):140–175. [PubMed] [Google Scholar]
39. Malanga GA, Ruoff GE, Weil AJ, et al. Cyclobenzaprine ER for muscle spasm associated with low dorsum and neck pain: ii randomized, double-blind, placebo-controlled studies of identical pattern. Electric current Medical Research and Stance. 2009;25(v):1179–1196. [PubMed] [Google Scholar]
40. Landy Southward, Altman CA, Xie F. Time to recovery in patients with astute painful musculoskeletal conditions treated with extended-release or firsthand-release cyclobenzaprine. Adv Ther. 2011;28(4):295–303. [PubMed] [Google Scholar]
41. Douglass MA, Levine DP. Hallucinations in an elderly patient taking recommended doses of cyclobenzaprine. Arch Intern Med. 2000;160(nine):1373. [PubMed] [Google Scholar]
42. Zanaflex tablets (tizanidine hydrochloride) bundle insert. Hawthorne, New York: Acorda Therapeutics Inc.; Jul, 2006. [Google Scholar]
43. Karoln D, Muzyk A, Preud'homme X. A instance of delirium, motor disturbance, and autonomic dysfunction due to baclofen and tizanidine withdrawal: a review of the literature. Gen Hosp Psychiatry. 2011;33(1):84.e1–2. [PubMed] [Google Scholar]
44. Kaddar N, Vigneault P, Pilote Due south, et al. Tizanidine (Zanaflex): A muscle relaxant that may prolong the QT interval past blocking IKr. J Cardiovasc Pharmacol Ther. 2012;17(1):102–109. [PubMed] [Google Scholar]
45. Valium (diazepam) package insert Nutley. New Bailiwick of jersey: Roche Laboratories Inc.; January, 2008. [Google Scholar]
Manufactures from Chemist's and Therapeutics are provided here courtesy of MediMedia, USA
Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4103716/
0 Response to "what is diazepam (valium)? benzodiazepine drug, used to treat spasticity in ms patients quizlet"
Post a Comment